Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
ERK1 and ERK2 associate with the tyrosine phosphatase
PTP-SL
through a kinase interaction motif (KIM) located in the juxtamembrane region of
PTP-SL
. A glutathione S-transferase (GST)-
PTP-SL
fusion protein containing the KIM associated with ERK1 and ERK2 as well as with p38/HOG, but not with the related JNK1 kinase or with protein kinase A or C. Accordingly, ERK2 showed in vitro substrate specificity to phosphorylate GST-
PTP-SL
in comparison with GST-
c-Jun
. Furthermore, tyrosine dephosphorylation of ERK2 by the PTP-SLDeltaKIM mutant was impaired. The in vitro association of ERK1/2 with GST-
PTP-SL
was highly stable; however, low concentrations of nucleotides partially dissociated the ERK1/2.
PTP-SL
complex. Partial deletions of the KIM abrogated the association of
PTP-SL
with ERK1/2, indicating that KIM integrity is required for interaction. Amino acid substitution analysis revealed that Arg and Leu residues within the KIM are essential for the interaction and suggested a regulatory role for Ser(231). Finally, coexpression of
PTP-SL
and ERK2 in COS-7 cells resulted in the retention of ERK2 in the cytoplasm in a KIM-dependent manner. Our results demonstrate that the noncatalytic region of
PTP-SL
associates with mitogen-activated protein kinases with high affinity and specificity, providing a mechanism for substrate specificity, and suggest a role for
PTP-SL
in the regulation of mitogen-activated protein kinase translocation to the nucleus upon activation.
...
PMID:Interaction of mitogen-activated protein kinases with the kinase interaction motif of the tyrosine phosphatase PTP-SL provides substrate specificity and retains ERK2 in the cytoplasm. 1041 10